ATE362929T1 - Pyridinderivate als inhibitoren der raf-kinase - Google Patents

Pyridinderivate als inhibitoren der raf-kinase

Info

Publication number
ATE362929T1
ATE362929T1 AT02779311T AT02779311T ATE362929T1 AT E362929 T1 ATE362929 T1 AT E362929T1 AT 02779311 T AT02779311 T AT 02779311T AT 02779311 T AT02779311 T AT 02779311T AT E362929 T1 ATE362929 T1 AT E362929T1
Authority
AT
Austria
Prior art keywords
kinase inhibitors
raf kinase
pyridine derivatives
raf
migraine
Prior art date
Application number
AT02779311T
Other languages
English (en)
Inventor
Mark Bamford
David Dean
Antoinette Naylor
Andrew Takle
David Wilson
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Application granted granted Critical
Publication of ATE362929T1 publication Critical patent/ATE362929T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Insulating Materials (AREA)
AT02779311T 2001-09-05 2002-09-05 Pyridinderivate als inhibitoren der raf-kinase ATE362929T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0121490.7A GB0121490D0 (en) 2001-09-05 2001-09-05 Ciompounds

Publications (1)

Publication Number Publication Date
ATE362929T1 true ATE362929T1 (de) 2007-06-15

Family

ID=9921558

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02779311T ATE362929T1 (de) 2001-09-05 2002-09-05 Pyridinderivate als inhibitoren der raf-kinase

Country Status (11)

Country Link
US (1) US7452906B2 (de)
EP (1) EP1423384B1 (de)
JP (1) JP2005504794A (de)
AT (1) ATE362929T1 (de)
CY (1) CY1106766T1 (de)
DE (1) DE60220290T2 (de)
DK (1) DK1423384T3 (de)
ES (1) ES2284939T3 (de)
GB (1) GB0121490D0 (de)
PT (1) PT1423384E (de)
WO (1) WO2003022840A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1050190A1 (zh) * 1999-11-22 2003-06-13 Smithkline Beecham Plc 咪唑衍生物和它们做为raf激酶抑制剂的用途
JP2003525936A (ja) * 2000-03-06 2003-09-02 スミスクライン ビーチャム パブリック リミテッド カンパニー Ｒａｆキナーゼ阻害物質としてのイミダゾール誘導体
GB0112348D0 (en) 2001-05-19 2001-07-11 Smithkline Beecham Plc Compounds
EP1432703A1 (de) * 2001-09-05 2004-06-30 Smithkline Beecham Plc Heterocycle-carboxamide derivate als raf kinase inhibitoren
US7473699B2 (en) 2002-02-28 2009-01-06 Astrazeneca Ab 3-cyclyl-5-(nitrogen-containing 5-membered ring)methyl-oxazolidinone derivatives and their use as antibacterial agents
RU2004129278A (ru) 2002-02-28 2005-06-10 Астразенека Аб (Se) Химические соединения
US20050176740A1 (en) * 2002-04-08 2005-08-11 Spector Neil L. Cancer treatment method comprising administering an erb-family inhibitor and a raf and/or ras inhibitor
US20050250837A1 (en) * 2002-10-18 2005-11-10 D Mello Santosh R Use of C-Raf inhibitors for the treatment of neurodegenerative diseases
US20090264494A1 (en) * 2002-10-18 2009-10-22 Board Of Regents, The University Of Texas System Use of neuroprotective 3-substituted indolone compositions
TW200639163A (en) * 2005-02-04 2006-11-16 Genentech Inc RAF inhibitor compounds and methods
JP2009514899A (ja) * 2005-11-04 2009-04-09 スミスクライン ビーチャム コーポレーション チエノピリジンＢ−Ｒａｆキナーゼ阻害剤
MX2010000617A (es) 2007-07-17 2010-05-17 Plexxikon Inc Compuestos y metodos para modulacion de cinasa, e indicaciones de estos.
US20110003859A1 (en) 2008-02-29 2011-01-06 Array Biopharma Inc. N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer
CL2009000448A1 (es) 2008-02-29 2009-11-27 Genentech Inc Compuestos derivados de 3-sulfonilamino-n-(1h-pirazolo-[3,4-b]piridin-5il)benzamida; procesos de preparacion; compuestos intermediarios; composicion farmaceutica; y uso para el tratamiento del cancer, tal como sarcoma, carcinoma, adenoma, entre otros.
CN102712646A (zh) 2009-08-28 2012-10-03 阵列生物制药公司 Raf抑制剂化合物及其使用方法
SG178900A1 (en) 2009-08-28 2012-04-27 Genentech Inc Raf inhibitor compounds and methods of use thereof
WO2011025951A1 (en) 2009-08-28 2011-03-03 Array Biopharma Inc. Raf inhibitor compounds and methods of use thereof
JP2013503189A (ja) 2009-08-28 2013-01-31 アレイ バイオファーマ、インコーポレイテッド Ｒａｆ阻害化合物およびその使用方法
EP2493865A2 (de) 2009-08-28 2012-09-05 Array Biopharma, Inc. Raf-hemmende verbindungen und anwendungsverfahren dafür
SG178561A1 (en) 2009-08-28 2012-03-29 Array Biopharma Inc 1h-pyrazolo [ 3, 4-b] pyridine compounds for inhibiting raf kinase
US8907098B2 (en) * 2009-12-17 2014-12-09 Merck Patent Gmbh Inhibitors of sphingosine kinase
WO2012118492A1 (en) 2011-03-01 2012-09-07 Array Biopharma Inc. Heterocyclic sulfonamides as raf inhibitors
WO2013109142A1 (en) 2012-01-16 2013-07-25 Stichting Het Nederlands Kanker Instituut Combined pdk and mapk/erk pathway inhibition in neoplasia
WO2015041533A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut Rock in combination with mapk-pathway
WO2015041534A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut P90rsk in combination with raf/erk/mek
WO2015095819A2 (en) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Cancer treatment using combinations of erk and raf inhibitors
US20190367457A1 (en) 2016-12-30 2019-12-05 Mitobridge, Inc. Oxopyridine derivatives useful as aminocarboxymuconate semialdehyde decarboxylase (acmsd) inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7629594A (en) 1993-07-21 1995-02-20 Smithkline Beecham Corporation Imidazoles for treating cytokine mediated disease
GB2306108A (en) * 1995-10-13 1997-04-30 Merck & Co Inc Treatment of Raf-mediated cancers with imidazole derivatives
EP1318992B1 (de) 2000-09-21 2005-07-27 Smithkline Beecham Plc Imidazolderivate als raf-kinase-inhibitoren

Also Published As

Publication number Publication date
ES2284939T3 (es) 2007-11-16
DE60220290T2 (de) 2008-01-31
DK1423384T3 (da) 2007-09-24
PT1423384E (pt) 2007-08-24
US20040235843A1 (en) 2004-11-25
US7452906B2 (en) 2008-11-18
GB0121490D0 (en) 2001-10-24
EP1423384A1 (de) 2004-06-02
EP1423384B1 (de) 2007-05-23
JP2005504794A (ja) 2005-02-17
DE60220290D1 (de) 2007-07-05
WO2003022840A1 (en) 2003-03-20
CY1106766T1 (el) 2012-05-23

Similar Documents

Publication Publication Date Title
ATE362929T1 (de) Pyridinderivate als inhibitoren der raf-kinase
DE60112312D1 (de) Imidazolderivate als raf-kinase-inhibitoren
DE60315146D1 (de) Heteroarylsubstituierte biphenylderivate als inhibitoren von p38-kinase
ATE435015T1 (de) Substituierte benzazole und ihre verwendung als raf-kinase-hemmer
ATE386034T1 (de) Pyrazoloisoquinolinenderivaten als kinase inhibitoren
ATE454152T1 (de) 2-aminopyrimidin-derivate als raf-kinase-hemmer
ATE408601T1 (de) Fredericamycin-derivate
GB0402143D0 (en) Novel compounds
NO20082414L (no) Inhibitorer av AKT-aktivitet
DK1864975T3 (da) Nikotinamid-derivater anvendelige som P38-inhibitorer
NO20070514L (no) Pyrrolotriazin kinase inhibitorer
DE60318177D1 (de) Rho-kinase inhibitoren
DE60228098D1 (de) Pyridin-substituierte furanderivate als raf-kinase inhibitoren
DK1325011T3 (da) Fremgangsmåder og forbindelser til behandling af proliferative sygdomme
GB0402138D0 (en) Novel compounds
DE60328603D1 (de) Prodrugs von imidazol-derivaten, zur verwendung als protonenpumpen-hemmer zur behandlung von z.b. peptischen magengeschwüren
ATE549024T1 (de) Chinazolin-kaliumkanalhemmer
ATE336489T1 (de) Stickstoff enthaltende heterozyklen und ihre verwendung als raf inhibitoren
NO20055307D0 (no) Substituerte isokromanforbindelser for behandling av metabolske forstyrrelser, kreft og andre sykdommer
ATE476419T1 (de) Isochinolinon-kaliumkanalinhibitoren
DE60316128D1 (de) N-sulfonylurea-apoptosis-förderer
DK1521752T3 (da) Makrocykliske forbindelser til behandling af cancer
EA200700098A1 (ru) Производные 4-арилморфолин-3-она, их получение и их применение в терапии
TW200602023A (en) Monocyclic heterocycles as kinase inhibitors

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1423384

Country of ref document: EP

REN Ceased due to non-payment of the annual fee